Esperion Therapeutics, Inc. (NASDAQ:ESPR) Expected to Post FY2025 Earnings of $0.02 Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research reduced their FY2025 earnings estimates for Esperion Therapeutics in a research report issued on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of $0.02 for the year, down from their prior estimate of $0.05. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

ESPR has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Monday, March 25th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, April 10th. Finally, Bank of America downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.33.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.99 on Tuesday. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40. The stock’s fifty day moving average price is $2.39 and its 200-day moving average price is $2.02.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the previous year, the company earned ($0.76) EPS.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Herbst Group LLC bought a new position in shares of Esperion Therapeutics during the 1st quarter valued at $28,000. Chicago Partners Investment Group LLC purchased a new position in Esperion Therapeutics during the third quarter valued at $29,000. Private Portfolio Partners LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter valued at approximately $30,000. Simplicity Solutions LLC bought a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $30,000. Finally, Simplicity Wealth LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.